Minister Simeon Brown looks on at Parliament on Jan. 28, 2025 in Wellington, New Zealand. Hagen Hopkins/Getty Images
New Zealand has announced a ban on new prescriptions of puberty-blocking medication for young people with gender dysphoria, aligning the country with similar policy shifts in the United Kingdom, Sweden, Finland, and Norway.
The drugs—gonadotropin-releasing hormone analogues—will remain available to those needing to take them for conditions with established clinical evidence, including early-onset puberty, endometriosis, or prostate cancer.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.
